Purpose: To examine the effect of EGD on Rx fill patterns for PPIs and nonselective NSAIDs in T2D and nondiabetic patients. Methods: Data on patients aged ≥18 y in the MarketScan administrative claims database with full enrollment data for 180 d pre- and post-EGD from 2000–2005 were extracted (D9612L00108). EGD was identified by CPT codes; T2D patients were identified as having ≥2 medical claims for T2D by ICD-9 codes or ≥2 oral antidiabetic Rxs; and nondiabetic patients were identified as having no ICD-9 codes for any type of diabetes or Rxs for antidiabetic medications. PPI and nonselective NSAID use were defined by national drug codes. T2D patients who underwent EGD were matched 1:1 with nondiabetic patients by age and gender. McNemar's test was used for proportion differences pre- and post-EGD; χ2 tests were used for differences between independent cohorts. Results: Of the 10,546,828 patients in the MarketScan database, 9,373,650 had no diabetes; 953,766 had T2D; 219,412 had other types of diabetes. In the matched population (N = 39,636 for each group), post-EGD, Rx fills increased for PPIs and decreased for nonselective NSAIDs (Table). Among patients already taking PPIs, 80.3% continued to use them post-EGD. Among patients not taking PPIs pre-EGD, 38.3% began using them post-EGD. The percentage of patients adding a PPI post-EGD was higher (P < .0001) for patients using (44.6%) than not using nonselective NSAIDs (37.9%). Of patients who took nonselective NSAIDs, 56.7% discontinued use post-EGD, and this proportion was lower (P < .0001) in patients who took (52.4%) than those who did not take concomitant PPIs (59.9%). No meaningful differences were seen between the T2D and nondiabetic groups. Conclusion: PPI use increased and nonselective NSAID use decreased post-EGD. Most patients who took only a nonselective NSAID pre-EGD discontinued NSAID use or had a PPI added to their regimen post-EGD. These results suggest that EGD findings had a direct effect on Rx fill patterns.Table: Rx Fills for PPIs and Nonselective NSAIDs Pre- and Post-EGD
Read full abstract